<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04173013</url>
  </required_header>
  <id_info>
    <org_study_id>2019-UROMUNEINM-EU</org_study_id>
    <nct_id>NCT04173013</nct_id>
  </id_info>
  <brief_title>Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI)</brief_title>
  <official_title>Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Impatients N.V. trading as myTomorrows</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inmunotek S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Impatients N.V. trading as myTomorrows</source>
  <brief_summary>
    <textblock>
      An Expanded Access Program for UROMUNE® for patients suffering from recurrent/chronic urinary
      tract infections of diverse etiology. This is for individuals for whom antibiotic therapy has
      failed, but of consideration in all cases, taking into account antibiotic-induced adverse
      reactions and increasing antibiotic resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      UROMUNE® is a mucosal immunotherapy indicated for the prevention of urinary tract infections
      caused by different pathogens. It works by stimulating the immune system, thus increasing the
      resistance against recurrent infections. The active substances are 4 inactivated and selected
      bacterial strains:

        -  Klebsiella pneumoniae 25%

        -  Escherichia coli 25%

        -  Enterococcus faecalis 25%

        -  Proteus vulgaris 25%
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Urinary Tract Infections</condition>
  <condition>Chronic Urinary Tract Infection</condition>
  <condition>Recurrent Urinary Tract Infection</condition>
  <condition>Urinary Tract Infection Bacterial</condition>
  <condition>Bladder Infection</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Uromune</intervention_name>
    <description>2 sprays of solution once daily for a total of 3 months.</description>
    <other_name>MV140</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients suffering recurrent urinary tract infections of diverse etiology.

        Exclusion Criteria:

          -  Individuals being allergic to any of the ingredients of UROMUNE®.

          -  Pregnancy and breast feeding. There are neither specific studies nor a formal
             contraindication, the physician should value benefits/risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Michel van Harten, MD</last_name>
    <phone>+31 885253888</phone>
    <email>inmunotek.medical@mytomorrows.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Belgium</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Czech Republic</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Denmark</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Finland</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>France</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Germany</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Luxembourg</name>
      <address>
        <city>Luxembourg</city>
        <country>Luxembourg</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>The Netherlands</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Norway</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Romania</name>
      <address>
        <city>Bukarest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Serbia</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Slovakia</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Slovenia</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Sweden</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Turkey</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Luxembourg</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>Sweden</country>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Benito-Villalvilla C, Cirauqui C, Diez-Rivero CM, Casanovas M, Subiza JL, Palomares O. MV140, a sublingual polyvalent bacterial preparation to treat recurrent urinary tract infections, licenses human dendritic cells for generating Th1, Th17, and IL-10 responses via Syk and MyD88. Mucosal Immunol. 2017 Jul;10(4):924-935. doi: 10.1038/mi.2016.112. Epub 2016 Dec 14.</citation>
    <PMID>27966556</PMID>
  </reference>
  <results_reference>
    <citation>Yang B, Foley S. First experience in the UK of treating women with recurrent urinary tract infections with the bacterial vaccine Uromune(®). BJU Int. 2018 Feb;121(2):289-292. doi: 10.1111/bju.14067. Epub 2017 Nov 23.</citation>
    <PMID>29171130</PMID>
  </results_reference>
  <results_reference>
    <citation>Lorenzo-Gómez MF, Padilla-Fernández B, García-Cenador MB, Virseda-Rodríguez ÁJ, Martín-García I, Sánchez-Escudero A, Vicente-Arroyo MJ, Mirón-Canelo JA. Comparison of sublingual therapeutic vaccine with antibiotics for the prophylaxis of recurrent urinary tract infections. Front Cell Infect Microbiol. 2015 Jun 3;5:50. doi: 10.3389/fcimb.2015.00050. eCollection 2015.</citation>
    <PMID>26090341</PMID>
  </results_reference>
  <results_reference>
    <citation>Ramírez Sevilla C, Gómez Lanza E, Manzanera JL, Martín JAR, Sanz MÁB. Active immunoprophyilaxis with uromune® decreases the recurrence of urinary tract infections at three and six months after treatment without relevant secondary effects. BMC Infect Dis. 2019 Oct 28;19(1):901. doi: 10.1186/s12879-019-4541-y.</citation>
    <PMID>31660885</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Cystitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

